Advertisement

Search Results

Advertisement



Your search for A. Oliver Sartor, MD,A. Oliver Sartor, MD matches 27 pages

Showing 1 - 27


prostate cancer
issues in oncology

Radioligand Therapy May Improve Radiographic Progression–Free Survival in Taxane-Naive Patients With Advanced Prostate Cancer

Lutetium (Lu)-177–PSMA-617 radioligand therapy may offer a statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with taxane-naive metastatic castration-resistant prostate cancer, according to findings presented by Herrmann et al at the 2024...

prostate cancer

Rapid Guideline Update on Radiotracers for Determining Radioligand Treatment Eligibility in Metastatic Castration-Resistant Prostate Cancer

ASCO has released a guideline rapid recommendation update addressing radiotracers used for prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) diagnostic imaging for selecting patients with metastatic castration-resistant prostate cancer (mCRPC) to receive...

prostate cancer

LuPSMA: Another Treatment Option for Metastatic Castration-Resistant Prostate Cancer

The use of lutetium-177–labeled PSMA-617 (LuPSMA) improved radiographic progression–free survival by 57% in men with metastatic castration-resistant prostate cancer who experienced disease progression on an androgen receptor (AR) pathway inhibitor compared with changing to a new AR pathway...

prostate cancer

PSMAfore: Lutetium Lu-177 Vipivotide Tetraxetan in Metastatic Prostate Cancer

Data from the phase III PSMAfore trial were presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract LBA13). Results showed that the trial of lutetium Lu-177 vipivotide tetraxetan met its primary endpoint, with a clinically meaningful and ...

Expert Point of View: Oliver Sartor, MD

The results of recent trials of PARP (poly [ADP-ribose] polymerase) inhibitor plus second-generation androgen receptor inhibitor combinations have had varying results in metastatic castration-resistant prostate cancer. Some trials suggest the benefit is confined to those with BRCA mutations and/or...

Expert Point of View: Oliver Sartor, MD

The results of recent trials of PARP (poly [ADP-ribose] polymerase) inhibitor plus second-generation androgen receptor inhibitor combinations have had varying results in metastatic castration-resistant prostate cancer. Some trials suggest the benefit is confined to those with BRCA mutations and/or...

prostate cancer

ASCO Treatment Guidance for Metastatic Castration-Resistant Prostate Cancer Updated to Include LuPSMA

An updated ASCO guideline recommends lutetium-177–labeled PSMA-617 (LuPSMA), a targeted radioligand therapy, for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with one prior line of androgen receptor pathway...

prostate cancer

LuPSMA Improves Progression-Free Survival vs Cabazitaxel in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Lutetium-177–labeled PSMA-617 (LuPSMA; lutetium Lu 177 vipivotide tetraxetan) achieved longer progression-free survival with fewer toxicities compared with cabazitaxel in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer whose disease...

prostate cancer

Expert Point of View: Elisabeth I. Heath, MD, FACP, and Oliver Sartor, MD

Formal discussant of the ARASENS trial, Elisabeth I. Heath, MD, FACP, Professor of Oncology and Associate Center Director, Translational Sciences, at Karmanos Cancer Institute in Detroit, commented on the changing paradigm in prostate cancer treatment. “The narrative is changing to triplet therapy, ...

prostate cancer

Study Reports Modest Gain in Progression-Free Survival With Continued Enzalutamide in Advanced Prostate Cancer

Enzalutamide is a common first-line choice for patients with metastatic castration-resistant prostate cancer, but response in some patients eventually wanes and then patients are switched to a different treatment. According to the phase IIIb PRESIDE trial, reported at the 2022 ASCO Genitourinary...

prostate cancer

Study Reports Modest Gain in Progression-Free Survival With Continued Enzalutamide in Advanced Prostate Cancer

Enzalutamide is a common first-line choice for patients with metastatic castration-resistant prostate cancer, but response in some patients eventually wanes and then patients are switched to a different treatment. According to the phase IIIb PRESIDE trial, reported at the 2022 ASCO Genitourinary...

prostate cancer

Expert Point of View: Elisabeth I. Heath, MD, FACP, and Oliver Sartor, MD

Formal discussant of the ARASENS trial, Elisabeth I. Heath, MD, FACP, Professor of Oncology and Associate Center Director, Translational Sciences, at Karmanos Cancer Institute in Detroit, commented on the changing paradigm in prostate cancer treatment. “The narrative is changing to triplet therapy, ...

prostate cancer

Adding LuPSMA to Standard Care Improves Outcomes in Castration-Resistant Prostate Cancer

As reported in The New England Journal of Medicine by Oliver Sartor, MD, of the School of Medicine, Tulane University, and colleagues, the phase III VISION trial has shown prolonged progression-free and overall survival with lutetium-177–PSMA-617 (LuPSMA) radioligand therapy plus standard care vs...

prostate cancer

VISION Trial: Lu-177–PSMA-617 Radioligand Therapy Prolongs Survival When Added to Standard of Care in Metastatic Castration-Resistant Prostate Cancer

As reported in The New England Journal of Medicine by Oliver Sartor, MD, and colleagues, the phase III VISION trial has shown prolonged progression-free and overall survival with lutetium-177–PSMA-617 (Lu-177–PSMA-617) radioligand therapy plus standard care vs standard care alone in previously...

Expert Point of View: Oliver Sartor, MD

Oliver Sartor, MD, Assistant Dean for Oncology and Professor at the Tulane University School of Medicine, New Orleans, commended Dr. Hofman and colleagues for completing a randomized phase II trial of lutetium-177–labeled prostate-specific membrane antigen (PSMA-617), or LuPSMA, so quickly. He...

prostate cancer

Is Nonmetastatic Castration-Resistant Prostate Cancer a Valid Disease Category?

Does nonmetastatic castration-resistant prostate cancer really exist? Although it is considered a disease category, it turns out that the definition depends on the type of imaging used. Many patients with castration-resistant prostate cancer who were categorized as “nonmetastatic” on conventional...

prostate cancer

Prevalence of Adverse Germline Genetic Variants in Prostate Cancer

In a study reported in JAMA Oncology by Nicolosi et al, it was found that 17% of men with prostate cancer had likely deleterious germline genetic variants, and that many of these men would not have been considered candidates for genetic testing. Study Details The study involved data from 3,607...

issues in oncology
palliative care
immunotherapy

A. Oliver Sartor, MD, on Issues in Immunotherapy

A. Oliver Sartor, MD, of Tulane University, speaks anecdotally about immunotherapy for prostate cancer and shares his experiences in speaking to patients with late-stage disease about the knowns, unknowns, risks, and toxicities of using a therapy outside the context of a clinical trial setting. The ...

prostate cancer

Sumanta K. Pal, MD, and A. Oliver Sartor, MD, on Prostate Cancer: Perspectives on Outcomes for Black and White Patients

Sumanta K. Pal, MD, of City of Hope, and A. Oliver Sartor, MD, of Tulane University School of Medicine, discuss the implications of findings on black and white patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate and prednisone (Abstract LBA5009).

prostate cancer

A. Oliver Sartor, MD, and Celestia S. Higano, MD, on Findings of the FIRSTANA Trial in Prostate Cancer

A. Oliver Sartor, MD, of Tulane University, and Celestia S. Higano, MD, of the University of Washington, discuss findings from this phase III study on cabazitaxel vs docetaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (Abstract 5006).

Expert Point of View: Oliver Sartor, MD

“This platform has no selection bias. Phlebotomy samples are drawn at key decision points. We begin to see that heterogeneity of circulating tumor cells predicted for shorter progression and survival times with selected androgen receptor–directed therapies. We need to study this prospectively,”...

prostate cancer

A. Oliver Sartor, MD, on Results of the ALSYMPCA Trial for Castration-Resistant Prostate Cancer

A. Oliver Sartor, MD, of Tulane University School of Medicine, discusses the latest results of a clinical trial on radium-223 dichloride and the improvement in overall survival of men with advanced prostate cancer (Abstracts 2510, 2530).

prostate cancer

A. Oliver Sartor, MD, on Advanced Prostate Cancer: Predicting Treatment Resistance

A. Oliver Sartor, MD, of Tulane Cancer Center, discusses this study investigating circulating tumor cell characteristics to predict resistance to androgen deprivation therapies in patients with advanced prostate cancer (Abstract 163).

prostate cancer

International Prostate Cancer Studies Report Inroads in Managing Bone Metastases

Treatment and prevention of bone metastases in patients with prostate cancer is coming of age, according to several studies presented at the European Multidisciplinary Cancer Congress (ECCO/ESMO/ESTRO). Among the most impressive studies reported was an international phase III trial of radium-223,...

Expert Point of View: Two Novel Agents Prolong Survival in Advanced Prostate Cancer

“My comment on the AFFIRM trial is ‘wow, very impressive.’ The median survival and the declines in PSA levels are impressive, and this is going to change the way we care for patients in our practices,” said Nicholas Vogelzang, MD, medical oncologist with Comprehensive Cancer Centers of Nevada and...

Expert Point of View: Short-term Hormone Therapy Did Not Increase Risk of Cardiovascular Death in Men with Localized Prostate Cancer, RTOG 94-08 Trial Finds

Oliver Sartor, MD, Medical Director of Tulane Cancer Center, New Orleans, said that in his opinion, RTOG 94-08 had some flaws because outdated radiotherapy doses were employed. “The utility of hormone therapy is questionable with today’s doses,” Dr. Sartor said. “Using standard radiation doses at...

prostate cancer

Radium-223 Dichloride Significantly Prolongs Time to First Symptomatic Skeletal Event in Patients With Castration-Resistant Prostate Cancer

In an article in The Lancet Oncology, Sartor et al report symptomatic skeletal event outcomes in the phase III ALSYMPCA trial, which was the study supporting the May 2013 approval of radium-233 dichloride (Xofigo) in patients with castration-resistant prostate cancer and bone metastases. They found ...

Advertisement

Advertisement




Advertisement